Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04993729 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
A Phase 3 study, sponsored by Tasly Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 853
- Enrollment target
NCT04993729 is a Phase 3 study that has completed, run by Tasly Pharmaceuticals. The registered enrollment target is 853 participants.
The verdict
NCT04993729, a Phase 3 study, has completed, sponsored by Tasly Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 853 participants
- Enrollment target
Study Summary
The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.
Interventions
- DRUG T89 capsule
- DRUG Placebo capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 853 participants |
| Start Date | 2021-07-21 |
| Est. Completion | 2023-05-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04993729
The ClinicalTrials.gov registry entry for NCT04993729 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 853 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tasly Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which T89 capsule is the first listed.
NCT04993729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04993729 about?
NCT04993729 is a clinical study titled "Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)". The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.
What is the current status of trial NCT04993729?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 853 participants. The study started on 2021-07-21. Estimated completion is 2023-05-26.
What interventions are being tested in trial NCT04993729?
The interventions under investigation include: T89 capsule (DRUG), Placebo capsule (DRUG).
Who is sponsoring clinical trial NCT04993729?
This trial is sponsored by Tasly Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.